R
Reneo Pharmaceuticals
Focused on the development of therapies for patients with genetically defined orphan diseases
About Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing therapies for rare genetic metabolic disorders. The company primarily focuses on conditions such as McArdle disease and primary mitochondrial myopathies (PMMs), which are characterized by severe muscle pain, weakness, and activity intolerance due to genetic mutations affecting muscle glycogen and mitochondrial function. Reneo's lead investigational compound, REN001, aims to enhance cellular energy metabolism by regulating genes involved in mitochondrial activity.
Reneo serves patients suffering from these rare diseases, operating in the biopharmaceutical market. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic compounds. Revenue generation is anticipated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical firms.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- Irvine, United States
- Listing
- IPO 2021
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 32.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Genetics and genomics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2024 | $0 | — | OnKure | ↗ |
| POST IPO EQUITYOther financing | May 2024 | $65M | — | Samsara BioCapital · Surveyor Capital · Vestal Point Capital · Cormorant Asset Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $375K | — | −$83M | -22102.1% |
| 2025 | $0 | — | −$83M | — |
| 2024 | $0 | — | −$83M | — |
| 2023 | $0 | — | −$83M | — |
| 2022 | $0 | — | −$54M | — |
| 2021 | $0 | — | −$40M | — |
| 2020 | $0 | — | −$20M | — |
Growth signals
Latest recorded traffic for Reneo Pharmaceuticals is 8.5K monthly website visits, up 12042.9% over the last three months. Reneo Pharmaceuticals's team declined 53.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
NEA
Lundbeckfonden Ventures
Pappas Capital
Abingworth
Novo Ventures
Aisling Capital
RiverVest Venture Partners
Rock Springs Capital- AIAmzak Health Investors
Series B and later7 investors entered at this stage
Samsara BioCapital
Surveyor Capital- VCVestal Point Capital
Cormorant Asset Management
Perceptive Advisors
Acorn Bioventures
Deep Track Capital
Other known investors1 additional known investor
OnKure
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reneo Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reneo Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.